Although recently PPARγ has been shown to inhibit cancer cell proliferation by reducing GSH level leading to excess ROS-induced cell-cycle arrest [45] and extensive studies have shown important roles of PPARγ in pancreatic cancer [41, 63–66], numerous studies have also documented tumor suppressive roles of PPARγ ligands independent of PPARγ activation, including but not restricted to an induction of apoptosis and ROS [67, 68]. Here, PPARG is linked to cancer.